Though most colorectal cancers show allelic losses, a subset of colorectal cancers (microsatellite instability or MSI-positive cancers) develop numerous small insertion and deletion mutations in repetitive DNA. Some of these sequences occur in coding regions of cancer related genes which, when targeted by frameshift mutations, produce truncations in their protein product. Such a gene is the proapoptotic tumor suppressor, BAX, mutated by frameshifts within a polyG sequence in approximately 50% of MSI-positive colorectal cancers. BAX is directly transactivated by p53, a gene commonly mutated in colorectal cancers but not often in MSI-positive lesions. Here we sought to characterize the relationship between BAX and p53 by simultaneously analysing a selected series of 65 colorectal tumors for mutations in the entire coding regions of both genes. The tumors comprised 19 MSI-high, 12 MSI-low and 34 MSI-null cancers. Eight of 19 MSI-high sporadic colorectal cancers (42%) contained insertions and deletions at the polyG tract in the BAX gene. In addition, three somatic BAX missense mutations were identi®ed in two tumors. A single missense mutation was detected in an MSI-high tumor that also contained a frameshift microdeletion, and two missense mutations were identi®ed in an MSI-null tumor wild-type for p53. p53 mutations were detected in 5/12 MSI-low tumors (42%) and 12/34 MSI-null tumors (35%). Of signi®cance, no p53 mutations were detected in MSI-high tumors. This study demonstrates that a reciprocal relationship exists between p53 and BAX in sporadic colorectal cancers, and further supports the hypothesis that MSI-low tumors are biologically similar to MSI-null tumors.
Development of colorectal cancer is a multistep process involving the accumulation of mutations in oncogenes and tumor suppressor genes such as APC, K-ras and p53 (Fearon and Vogelstein, 1990) . The majority of colorectal cancers show multiple allelic losses, but a subset, defective in DNA mismatch repair, display numerous mutations in repetitive sequences. This feature is called microsatellite instability and tumors bearing it are described as having an MSI-positive phenotype. It is present in the majority of HNPCC and approximately 10% of sporadic colorectal cancers (Ionov et al., 1993; Lothe et al., 1993; Thibodeau et al., 1993; Aaltonen et al., 1994) , as well as in tumors arising in extracolonic sites such as the stomach (Rhyu et al., 1994) . In addition to containing widespread microsatellite instability at anonymous sequences, most tumors with this mutator phenotype harbor frameshift mutations in coding mononucleotide repeat sequences in cancer related genes TGFb RII, IGF-IIR, BAX, hMSH3, hMSH6 and E2F-4 Souza et al., 1996 Souza et al., , 1997a Yoshitaka et al., 1996; Rampino et al., 1997; Yin et al., 1997b; Perucho, 1996) . Accumulating evidence suggests that tumorigenic pathways, characterized on the one hand by allelic losses and on the other by microsatellite instability, represent alternative processes (reviewed in Kinzler and Vogelstein, 1996) . APC and K-ras mutations have been found in MSI-positive cancers Huang et al., 1996) but their p53 status remains unclear. Negative correlations between p53 mutations and MSI status have been described in sporadic colorectal cancers (Ionov et al., 1993; Kahlenberg et al., 1996) and colorectal cancer cell lines (Cottu et al., 1996) , though Aaltonen et al., (1993) found no evidence of this. Similarly, a negative association between microsatellite instability and p53 gene mutation has been shown to also exist in gastric cancer (Strickler et al., 1994; Renault et al., 1996) . Other studies have found a low frequency of p53 gene mutations in mucinous and right-sided colorectal cancers (Hanski et al., 1996 and Watatani et al., 1996 respectively) . Both mucinous and right-sided features are characteristic of the MSI-positive phenotype (Jass et al., 1998) implying that the low frequency of p53 mutations may correlate directly with the MSI-high phenotype rather than presence of mucin and tumor location.
The p53 tumor suppressor gene is involved in the induction of G1-phase cell cycle arrest or apoptosis in response to cellular stress such as DNA damage and hypoxia (Kastan et al., 1991; Kuerbitz et al., 1992; Lin et al., 1992; Clark et al., 1993; Di Leonardo et al., 1994; Smith et al., 1995; Graeber et al., 1996) . Loss of p53 function by mutation or deletion is associated with increased chromosomal instability, an increased susceptibility to malignant transformation (Livingstone et al., 1992; Yin et al., 1992; Donehower et al., 1992; Jacks et al., 1994) , inhibition of apoptosis (YonishRouach et al., 1991) and an increased resistance to the anti-cancer treatments, cisplatin and ionizing radiation (McIlwrath et al., 1994; Lee and Bernstein 1993; Lowe et al., 1993 respectively) . Downstream targets of p53 central to the regulation of growth control include p21 CIP1/WAF1 , GADD45, MDM2, BAX and IGF-BP (ElDeiry et al., 1993; Kastan et al., 1992; Barak et al., 1993; Zhan et al., 1994; Buckbinder et al., 1995) . The tumor suppressor gene BAX, , which is directly transactivated by wild-type p53 (Miyashita and Reed, 1995) and which induces apoptosis in response to toxic stress, has recently been shown to contain inactivating mutations within an 8 bp coding polyguanine tract in more than 50% of MSI-positive sporadic colorectal cancers and in some MSI-positive colorectal cancer cell lines (Rampino et al., 1997) . With reports of negative associations between p53 mutations and MSI status, and the frequent loss of BAX function described in MSI-positive cells, we sought to further characterize the p53-dependent apoptotic pathway by investigating the relationship between p53 and BAX mutations in a well-de®ned group of MSI-positive and MSI-negative sporadic colorectal cancers.
Tumors were assessed for microsatellite instability at loci MYCL, AT3, D2S123, F13B, BAT26 and BAT40 ( Figure 1a ,b) as previously reported Simms et al., 1997) . Patients meeting the criteria for HNPCC were excluded from this study (Vasen et al., 1991) . Tumors manifesting instability were classi®ed as either MSI-high if instability was demonstrated at three or more loci (including one mononucleotide repeat), or MSI-low if present in up to two loci (Jass et al., 1998) . A total of 65 tumors from 61 patients including 19 MSI-high, 12 MSI-low and 34 MSI-null cancers were selected for this study from the consecutive series previously described in Simms et al., (1997) on the basis of MSI status and DNA availability. Genetic alterations in the coding 8-guanine repeat in the BAX gene ( Figure 1c ) were analysed as previously described (Rampino et al., 1997) . Eight of 19 MSI-high sporadic colorectal cancers (42%) showed evidence of insertions and deletions at the polyG tract in the BAX gene. Five tumors contained deletion mutations, two tumors had an insertion mutation and one tumor had both an insertion and deletion mutation in the BAX gene. BAX frameshift mutations were not detected in the group of tumors with MSI-low positivity (0/12) nor the MSInull group (0/34) (P50.001).
So as not to under-report the frequency or distribution of mutations, SSCP analysis was performed on the entire open reading frames of both p53 and BAX. Exons 2 through 11 of the p53 gene and exons 1 through 6 of BAX were ampli®ed using speci®c intronic oligonucleotides (Mashiyama et al., 1991; Kastrinakis et al., 1995; Chou et al., 1996) . p53 mutations were detected in 17 of 65 tumors (26%) ( Table 1) . Five of 12 MSI-low and 12 of 34 MSI-null tumors (42% and 35% respectively) contained mutations of the p53 gene. Two tumors each contained two p53 mutations. Of note, all MSI-positive tumors were wild-type for p53 (P50.001). No mutations were identi®ed in exons 2, 3, 9 or 11. Of 20 mutations identi®ed in 17 tumors, 14 were missense mutations, three were nonsense mutations and three were deletions. The majority of mutations (15/20) occurred within the conserved central DNA binding domain. Of the 15 tumors with mutations within this region, recurrent point mutations were present at codons 176 and 306 (four tumors and three tumors respectively). BAX mutations (additional to those occurring in the polyG tract) were found in two tumors. A G11E mutation was detected in an MSI-high tumor which also carried a G 8 deletion, and two missense mutations (A183T and L185P, Figure 2a ,b) were identi®ed in an MSI-null tumor wild-type for p53 ( Table 2 ). Both of these mutations occur at the carboxyl end of the molecule in a region containing a mutational hotspot. Most recently, Yamamoto et al., (1997) also demonstrated somatic BAX mutations other than frameshifts in G 8 in gastric and colorectal cancers. In some of these, as in this study, there was evidence of bi-allelic activation. Of note, no tumors in this study contained both BAX and p53 mutations, suggesting a negative association between them (P=0.033, Fisher's Exact Test). The overall results of p53 and BAX mutational analysis with respect to MSI status are shown in Table 3 .
To our knowledge, this is the ®rst report to simultaneously describe the distribution of both p53 and BAX mutations in sporadic colorectal tumors characterized for the presence of microsatellite instability. Whilst the frequency of BAX mutations is in agreement with recent ®ndings (Rampino et al., 1997; Yamamoto et al., 1997) , the low rate of p53 mutations overall in this study may be explained by the disproportionate number of MSI-high tumors, as this was a selected series. All MSI-positive tumors and a subset of the remaining tumors had been previously characterized for p53 immunohistochemistry (Biden et al., unpublished results). In that study, the average score for p53 positive staining in the MSI-high tumors was 55% of cells. In contrast, the average score for MSI-low and MSI-null tumors was 50% of cells, supporting the results seen here. Interestingly, the MSInull tumor with two BAX missense mutations, showed no staining for p53 suggesting the presence of wild-type protein. In the present study, we have shown that a reciprocal relationship exists between the tumor suppressors p53 and BAX, further supporting evidence that MSI-high tumors develop via alternative mutations in a serial pathway. The existence of an MSI-null tumor with bi-allelic BAX inactivation and no evidence of p53 gene mutation suggests that the reciprocal relationship exists regardless of the presence or absence of functioning mismatch repair. This study also adds further con®rmation to the ®nding that MSIlow tumors are biologically similar to MSI-null tumors (Jass et al., 1998) .
Both p53 and BAX regulate entry to a pathway of apoptosis. Activation of functional p53 simultaneously induces an up-regulation of BAX and a downregulation of Bcl-2 (Zhan et al., 1994) . p53 gene mutations impairing or inactivating this pathway result in loss of apoptotic function and accelerated tumor growth in vivo (Zhan et al., 1994; Yin et al., 1997a) . The presence of somatic BAX mutations in eight of 19 MSI-high sporadic colorectal cancers (42%) and in one MSI-null lesion provides a mechanism by which tumor cells with wild-type p53 could also escape apoptosis. Given that the majority of cytotoxic anticancer drugs and ionizing radiation kills tumor cells primarily by inducing apoptosis, an impairment or loss of apoptotic function by either mutations in p53 or BAX would play a major role in the development of resistance to such treatments. Recently, a role for p53 gene mutations in the development of cisplatin resistance as a consequence of reduced transactivation of BAX was demonstrated in an ovarian cancer cell line (Perego et al., 1996) . In addition, a short structural domain of p53 conferring resistance to cisplatin in an ovarian cancer cell line has recently been identi®ed (Gallagher et al., 1997) . Decreased levels of BAX have also been reported to occur in malignant cells from breast cancer patients with poor chemotherapeutic responses (Bargou et al., 1995; Krajewski et al., 1995) .
Hence, it is possible that mutations in p53 or its downstream target BAX present an opportunity for colorectal cancer cells to escape from programmed cell death. It is not feasible to correlate apoptosis counts in this tumour series with the results presented here due to the fact that our tumors were collected by surgical resection. The blood supply to the colon is ligated for at least 20 min prior to removal from the patient. This may activate or augment apoptosis via the p53/BAX or alternative pathways.
However, studies of apoptosis in isogenic cell lines diering only by their p53 and BAX mutant status could further illuminate whether an apoptosis threshhold is reached when one of these genes is inactivated. In addition, in vitro malignant transformation assays could be performed with cellular knockouts of p53 and/or BAX to determine whether mutation of one or both genes is required for neoplastic progression.
In conclusion, colorectal tumors with defective mismatch repair commonly develop with intact p53 function. Loss of BAX function in a subset of these tumors may cause a reduction in p53-mediated apoptosis in response to DNA damage and other forms of cellular stress thus contributing to tumorigenesis in the presence of normal p53. As more than 50% of tumors in this study did not have mutations in either p53 or BAX it is possible that there are other pathways by which colorectal tumors may escape apoptosis. 
